AnaptysBio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 163.62 million compared to USD 128.72 million a year ago. Basic loss per share from continuing operations was USD 6.08 compared to USD 4.57 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.1 USD | +1.90% | -3.29% | +12.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.51% | 658M | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+1.98% | 22.58B | |
-14.29% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023